OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

CEO

Mr. Joshua Riggs

Employees

Country

United States

ISIN

US68235C1071

Listings

0 Comments

Share your thoughts

FAQ

What is OncoCyte stock price today?▼

The current price of OCX is $3.20 USD — it has increased by +17.22% in the past 24 hours. Watch OncoCyte stock price performance more closely on the chart.

What is OncoCyte stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange OncoCyte stocks are traded under the ticker OCX.

What is OncoCyte revenue for the last year?▼

OncoCyte revenue for the last year amounts to 1.88M USD.

What is OncoCyte net income for the last year?▼

OCX net income for the last year is -60.66M USD.

How many employees does OncoCyte have?▼

As of September 08, 2026, the company has 46 employees.

In which sector is OncoCyte located?▼

OncoCyte operates in the Health & Wellness sector.

When did OncoCyte complete a stock split?▼

The last stock split for OncoCyte was on July 25, 2023 with a ratio of 1:20.

Where is OncoCyte headquartered?▼

OncoCyte is headquartered in Irvine, United States.